This Article Full Text Full Text (PDF) All Versions of this Article: 114/24/2636    most recent CIRCULATIONAHA.106.638627v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertrand, O. F. Search for Related Content PubMed PubMed Citation Articles by Bertrand, O. F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty Blood Thinners Related Collections Platelet function inhibitors Catheter-based coronary interventions: stents Acute coronary syndromes Related Article

(Circulation. 2006;114:2636-2643.)
© 2006 American Heart Association, Inc.

Interventional Cardiology

A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation

Olivier F. Bertrand, MD, PhD; Robert De Larochellière, MD; Josep Rodés-Cabau, MD; Guy Proulx, MD; Onil Gleeton, MD; Can Manh Nguyen, MD; Jean-Pierre Déry, MD, MSc; Gérald Barbeau, MD; Bernard Noël, MD; Éric Larose, DVM, MD; Paul Poirier, MD, PhD; Louis Roy, MD, for the Early Discharge After Transradial Stenting of Coronary Arteries (EASY) Study Investigators

From the Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie, affilié à l’Université Laval, Québec, Canada.

Correspondence to Dr Olivier F. Bertrand, MD, PhD, Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie, affilié à l’Université Laval, 2725 Chemin Ste Foy, Québec, Canada G1V 4G5. E-mail Olivier.Bertrand{at}crhl.ulaval.ca

Received May 11, 2006; revision received September 18, 2006; accepted September 22, 2006.

Background— Systematic use of coronary stents and optimized platelet aggregation inhibition has greatly improved the short-term results of percutaneous coronary interventions. Transradial percutaneous coronary interventions have been associated with a low risk of bleeding complications. It is unknown whether moderate- and high-risk patients can be discharged safely the same day after uncomplicated transradial percutaneous coronary interventions.

Methods and Results— We randomized 1005 patients after a bolus of abciximab and uncomplicated transradial percutaneous coronary stent implantation either to same-day home discharge and no infusion of abciximab (group 1, n=504) or to overnight hospitalization and a standard 12-hour infusion of abciximab (group 2, n=501). The primary composite end point of the study was the 30-day incidence of any of the following events: death, myocardial infarction, urgent revascularization, major bleeding, repeat hospitalization, access site complications, and severe thrombocytopenia. The noninferiority of same-day home discharge and bolus of abciximab only compared with overnight hospitalization and abciximab bolus and infusion was evaluated. Two thirds of patients presented with unstable angina and 20% presented with high-risk acute coronary syndrome prior to the procedure. The incidence of the primary end point was 20.4% in group 1 and 18.2% in group 2 (P=0.017 for noninferiority) with a troponin T–based definition of myocardial infarction; the incidence of the primary end point was 11.1% in group 1 and 9.6% in group 2 (P=0.0004 for noninferiority) with a creatinine kinase myocardial band–based definition of myocardial infarction. No death occurred. Rate of major bleeding in both groups was extremely low at 0.8% and 0.2%, respectively. From 504 patients randomized in group 1, 88% were discharged home the same day.

Conclusion— Our data suggest that same-day home discharge after uncomplicated transradial coronary stenting and bolus only of abciximab is not clinically inferior, in a wide spectrum of patients, to the standard overnight hospitalization and a bolus followed by a 12-hour infusion. This novel approach offers a safe strategy for same-day home discharge after uncomplicated coronary intervention.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2006 114: 2571. [Extract] [Full Text]

This article has been cited by other articles:

				A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, et al. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 837 - 845. [Abstract] [Full Text] [PDF]

				E. Mahmud and A. Prasad Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 846 - 848. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]

				F. S. Resnic The Case for Outpatient Coronary Intervention: Balancing Charges and Discharges Circulation, May 1, 2007; 115(17): 2248 - 2250. [Full Text] [PDF]

				T. A. Mixon and G. J. Dehmer Drive-Through Angioplasty: Is It Safe or Necessary? Circulation, December 12, 2006; 114(24): 2578 - 2580. [Full Text] [PDF]